HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

House FDA reform national uniformity provision acknowledges state tort rights.

This article was originally published in The Rose Sheet

Executive Summary

HOUSE FDA REFORM NATIONAL UNIFORMITY PROVISION ACKNOWLEDGING STATE TORT RIGHTS is included in a revised draft of Rep. Richard Burr's (R-N.C.) drugs and biologics bill (HR 3199). The new draft, released July 10, includes a clarification, which states that "nothing in the [national uniformity] section shall be construed to modify or otherwise affect any action or the liability of any person under the generally applicable tort law of any state."
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS002986

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel